Wow, they're really 'moving' (that is, multiple companies/organizations
now have interest).

 January 19, 2005 09:00 AM US Eastern Timezone

Advanced Biotherapy Completes Investigational Pilot Clinical Trial in
Genital Herpes

WOODLAND HILLS, Calif.--(BUSINESS WIRE)--Jan. 19, 2005--Advanced
Biotherapy, Inc. (OTCBB:ADVB), dedicated to pioneering the development
and use of therapeutic antibodies, announced that the Company completed
a pilot investigational study using antibodies to interferon-gamma in
the treatment of patients suffering from Genital Herpes at the
Department of Skin and Venereal Diseases, Russian State Medical
University, Moscow, Russia.

Mr. Edmond Buccellato, President and CEO, stated, "Patients with
recurrent herpes simplex virus type 2 (HSV-2) genital lesions were
treated topically for several days with our investigational antibodies
to interferon-gamma. Our principal investigators reported that itching
and pain were relieved within hours of the application of the antibody,
and the eroded area of the skin epithelialized within 3-4 days.
Observation continues. Research indicates that the HSV-2 causing
recurrent genital lesions may belong to a special category of viruses,
such as HIV and certain other viruses, in which interferons promote
rather than stop viral replication. The idea of such a category of
viruses was proposed several years ago by Dr. S. Skurkovich, our head of
research and development."

Genital herpes, for which there is no specific cure, is almost always
sexually transmitted. It can be a very painful disease manifested as a
rash, bumps, blisters, cuts, or sores in or around the genital area
accompanied by itching, burning, tingling, or swelling.

Mr. Buccellato concluded, "We continue to significantly expand our
intellectual property estate regarding 'field of use' not only related
to antibodies and other inhibitors to interferon-gamma, but also for use
of inhibitors to other cytokines, such as TNF-a and IL-1, for
therapeutic purposes."

According to the U.S. Centers for Disease Control and Prevention, 45
million people in the United States ages 12 and older, or 1 out of 5 of
the total adolescent and adult population, are infected with HSV-2.
Because the infection is so widespread, the Company puts great
significance on this work.

About Advanced Biotherapy

The Company, a pioneer in anticytokine therapy, has demonstrated the
effectiveness of its pioneering scientific strategy by conducting
investigational clinical trials treating patients suffering from AIDS,
multiple sclerosis, rheumatoid arthritis, corneal transplant rejection
and certain autoimmune skin conditions, including psoriasis, and
alopecia, all Th1 mediated autoimmune diseases which appear to have the
same proinflammatory Th-1 activity. Advanced Biotherapy is headquartered
in Los Angeles with laboratories in Columbia, Maryland. The company has
an extensive patent portfolio including 7 issued patents and over 38
patents pending.

Statements made in this news release, other than statements of
historical fact, are forward-looking statements and are subject to a
number of uncertainties that could cause actual results to differ
materially from the anticipated results or other expectations expressed
in our forward-looking statements. Some of these forward-looking
statements may be identified by the use of words in the statements such
as "appears," "may," "goal," "anticipate," "estimate," "expect,"
"project," "intend," "plan or plans," "believe," "could," or other words
and terms of similar meaning. The risks and uncertainties which may
affect the development, operations and results of our business include,
but are not limited to the following: risks associated with clinical
trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory approval process, the risks of
competitive products, the risks of our current capital resources, the
uncertainties as to the availability of future capital and our future
capital requirements, and the risks associated with the extent and
breadth of the Company's patent portfolio. There are no assurances that
the Company's product candidates will receive regulatory approval. The
foregoing discussion of the pending clinical investigations and the
effect of the patents issued and pending involves risks and
uncertainties, including but not limited to the risks that third parties
may be successful in challenging such patents; or that granted claims
may be held invalid or interpreted differently by a court of law; or
that new technologies will be developed that are superior in treating
the diseases targeted by Advanced Biotherapy, Inc. Readers are cautioned
not to place reliance on these forward-looking statements, which speak
only as of the date the statements were made. See the Company's public
filings with the Securities and Exchange Commission for further
information about risks and uncertainties that may affect the Company
and the results or expectations expressed in our forward-looking
statements, including the section captioned "Factors That May Affect The
Company" contained in the Company's Annual Report on Form 10-KSB for the
fiscal year ended December 31, 2003.
   
Contacts
       
   
Advanced Biotherapy, Inc.
Edmond Buccellato or Amy Buccellato, 818-883-6716
Fax: 818-883-3353
ed@advancedbiotherapy.com
amy@advancedbiotherapy.com
www.advancedbiotherapy.com